

Please type a plus sign (+) inside this box



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application Number	09/155,739
Filing Date	September 11, 1998
First Named Inventor	Mary M. Bendig
Group Art Unit	1644
Examiner Name	Gambel, P.
Attorney Docket Number	015270-001430US

Sheet 1 of 3

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
	1	5,260,210		Rubin et al.	11-09-1993	
	2	5,530,101		Queen et al.	06-25-1996	
	3	5,840,299		Bendig, et al.	11-24-1998	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
	4	EP	EP239400			09-30-1987		
	5	EP	EP330506			08-19-1989		
	6	PCT	WO 90/07861			07-26-1990		
	7	PCT	WO 91/03252			03-21-1991		
	8	PCT	WO 91/05038			04-18-1991		
	9	PCT	WO 93/15764			08-19-1993		
	10	PCT	WO 95/19790			01-25-1995		

Examiner Signature

Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PA 3173153 v2

Please type a plus sign (+) inside this box



PTO/SB/08B (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet **2** of **3**

Complete if Known

Application Number	09/155,739
Filing Date	September 11, 1998
First Named Inventor	Mary M. Bendig
Group Art Unit	1644
Examiner Name	Gambel, P.
Attorney Docket Number	015270-001430US

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	11	ALBELDA, "Adhesion molecules and inflammatory injury," FASEB J. 8: 504-512 (1994).	
	12	CANNELLA et al., "The Adhesion Molecule and Cytokine Profile of Multiple Sclerosis Lesions," Ann Neurol. 37: 424-435 (1995).	
	13	DALAKAS, "Basic Aspects of Neuroimmunology as They Relate to Immunotherapeutic Targets: Present and Future Prospects," Ann. Neurol. 37(51): 52-513 (1995).	
	14	DIJKSTRA et al., "Multiple sclerosis: some possible therapeutic opportunities," Tips Reviews, vol. 14, pp. 124-129 (1993).	
	15	DORE-DUFFY et al., in <u>Frontiers in Cerebral Vascular Biology: Transport and its Regulation</u> Dreues and Betz (eds) Plenum Press N.Y. pp. 243-248 (1993).	
	16	EDGINGTON, "How Sweet It Is: Selectin-Mediating Drugs," Bio/Technology, vol. 10, pp. 383-389 (1992).	
	17	ELICES et al., "VCAM-1 on Activated Endothelium Interacts with the Leukocyte Integrin VLA-4 at a Site Distinct from the VLA-4/Fibronectin Binding Site," Cell, vol. 60, pp. 577-584 (1990).	
	18	EMERY et al., "Humanised monoclonal antibodies for therapeutic applications," Exp. Opin. Invest. Drugs, vol. 3, pp. 241-251 (1994).	
	19	HARRIS et al., "Therapeutic antibodies--the coming of age," Tibtech, vol. 11, pp. 42-45 (1993).	
	20	JOLLIFFE, "Humanized Antibodies: Enhancing Therapeutic Utility Through Antibody Engineering," Intern Rev Immunol, vol. 10, pp. 241-250 (1993).	
	21	KAHAN, "Immunosuppressive therapy," Curr Opin Immunology 4: 553-560 (1992).	
	22	KARUSSIS et al., "Treatment of chronic-relapsing experimental autoimmune encephalomyelitis with the synthetic immunomodulator linomide (quinoline-3-carboxamide)," PNAS 90: 6400-6404 (1993).	
	23	KETTLEBOROUGH et al., "Humanization of a mouse monoclonal antibody by CDR-grafting the importance of framework residues on loop conformation," Protein Engineering, vol. 4, No. 7, pp. 773-783 (1991).	
	24	LISAK et al., "Effect of treatment with copolymer 1 (cop-1) on the in vivo and in vitro manifestations of experimental allergic encephalomyelitis (EAE)," J. Neurol. Sciences 62: 281-293 (1983).	
	25	MONSHIZADEGAN et al., "VLA-4-dependent adhesion activities of U937 cells and guinea pig bronchoalveolar lavage leukocytes," Agents Actions 39, pp. C177-C179 (1993).	

Examiner
Signature

Date
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
PA 3173153 v2

Please type a plus sign (+) inside this box



PTO/SB/08B (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 3 of 3

Complete if Known

Application Number	09/155,739
Filing Date	September 11, 1998
First Named Inventor	Mary M. Bendig
Group Art Unit	1644
Examiner Name	Gambel, P.
Attorney Docket Number	015270-001430US

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	26	³ MOUNTAIN et al., "Engineering Antibodies for Therapy," Biotech Genetic Engineering Reviews, vol. 10, pp. 10-13 (1992).	
	27	³ NATANSON et al., "Selected Treatment Strategies for Septic Shock Based on Proposed Mechanisms of Pathogenesis," Ann Intern Med. 120: 771-783 (1994).	
	28	³ PAUL (ed), <u>Fundamental Immunology</u> Raven Press NY p. 242 only (1993).	
	29	³ RACKE et al., "Long-term treatment of chronic relapsing experimental allergic encephalomyelitis by transforming growth factor- β 2," J. Neuroimmunol. 46: 175-184 (1993).	
	30	³ TEITELBAUM et al., "Synthetic copolymer 1 inhibits human T-cell lines specific for myelin basic protein," PNAS 89: 137-141 (1992).	
	31	³ WARD et al., "Blocking of adhesion molecules in vivo as anti-inflammatory therapy," Therapeutic Immunol, vol. 10, pp. 165-171 (1994).	
	32	³ WASHINGTON et al., "Expression of Immunologically Relevant Endothelial Cell Activation Antigens on Isolated Central Nervous System Microvessels from Patients with Multiple Sclerosis," Ann Neurol 35: 89-97 (1994).	
	33	³ WEINER et al., "Double-Blind Pilot Trial of Oral Tolerization with Myelin Antigens in Multiple Sclerosis," Science 259: 1321-1324 (1993).	
	34	³ YEDNOCK et al., "Prevention of experimental autoimmune encephalomyelitis by antibodies against α 4 β 1 integrin," Letters to Nature, vol. 356, pp. 63-66 (1991).	

Examiner
Signature

Date
Considered

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
PA 3173153 v2